<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852537</url>
  </required_header>
  <id_info>
    <org_study_id>18-010925</org_study_id>
    <nct_id>NCT03852537</nct_id>
  </id_info>
  <brief_title>Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia</brief_title>
  <official_title>SMART Trial: Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to determine the appropriate dose of steroids and the&#xD;
      appropriate duration for steroid use to reduce inflammation in severe pneumonia needing a&#xD;
      form of breathing support. This study seeks to compare usual care to a unique&#xD;
      (individualized) dosing strategy. A marker of inflammation in the body will be measured in&#xD;
      blood samples. This marker of inflammation is called C- reactive protein. The overall goal is&#xD;
      to identify patients that will benefit most from steroid use and decrease use of steroids.&#xD;
      The information collected from this study may provide information that may improve management&#xD;
      of patients with severe pneumonia requiring a form of breathing support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-arm single-center pilot phase II clinical trial. Patients will be screened at&#xD;
      the time of hospital admission and will be required to be enrolled within the clinical trial&#xD;
      within 48 hours of hospital admission.&#xD;
&#xD;
      In the individualized, biomarker-concordant arm, all patients will receive steroids once at&#xD;
      the time of admission, then a daily morning dose. In order to account for varying turnaround&#xD;
      time at different laboratories, C-Reactive Protein (CRP) levels will be drawn with early&#xD;
      morning labs, and used to determine the steroid dosing for the day. Patients will receive&#xD;
      daily CRP measurements for the first 5 days of the hospitalization, or until hospital&#xD;
      discharge. CRP measurements will be discontinued once the CRP is less than 50mmol/L.&#xD;
&#xD;
      Steroid administration will be facilitated using standardized computerized physician order&#xD;
      entry. The patients, treating physicians and outcome assessors will be blinded to the group&#xD;
      assignment. Steroid order sets will include 6 hourly point of care glucose monitoring, and an&#xD;
      insulin sliding scale for glucose levels to facilitate glucose management. The need for&#xD;
      insulin drip will be determined by the treating physician. Additional testing including serum&#xD;
      and urine ketones will be informed by the glucose level, serum anion gap and bicarbonate&#xD;
      levels in routine basic metabolic panels and determined by the treating physician.&#xD;
&#xD;
      In the usual care arm, patients will receive daily CRP measurements for the first 5 days of&#xD;
      the hospitalization, or until hospital discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Actual">November 17, 2020</completion_date>
  <primary_completion_date type="Actual">November 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing</measure>
    <time_frame>Within 30 days of enrollment in study.</time_frame>
    <description>Number of eligible subjects to adhered to the timely initiation and daily corticosteroid treatment according to ESICM/Society of Critical Care Medicine SCCM clinical practice guideline (control group) or biomarker concordance (intervention group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Number of subject deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for High Flow Nasal Cannula Oxygen</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Number of subjects to need high flow nasal cannula oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Noninvasive Mechanical Ventilation</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Assessed by the number of participants that required noninvasive mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Invasive Mechanical Ventilation</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Assessed by the number of participants that required invasive mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Failure</measure>
    <time_frame>Measured daily for approximately 5 days</time_frame>
    <description>Organ failures measured by Sequential Organ Failure Assessment (SOFA). The overall score is based on 6 sub-scores respiratory system, neurologic system, cardiovascular system, hepatic system, coagulation, and renal system using an overall scale of 0-24, which 0=no organ failure, 24=complete organ failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onset Cardiac Arrhythmias</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Number of participants who develop arrhythmias identified by electrocardiogram or echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Injury</measure>
    <time_frame>Up to day +14 following study enrollment.</time_frame>
    <description>Number of participants with evidence of myocardial injury determined by daily troponin peak and /or new diagnosis of Left Ventricular (LV) dysfunction (LVEF &lt;40%) or new diagnosis of cor pulmonale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Dysfunction</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Number of subjects with new and/or worsening right ventricle (RV)/left ventricle (LV) dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Hyperglycemia</measure>
    <time_frame>Up to day +5 following study enrollment.</time_frame>
    <description>Number of participants who have hyperglycemia while receiving corticosteroids. Hyperglycemia is defined as a consistently elevated blood sugar level requiring insulin administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Delirium</measure>
    <time_frame>Up to day +5 following study enrollment.</time_frame>
    <description>Number of participants who develop delirium while receiving corticosteroids. Delirium will be assessed by Confusion Assessment Method for the ICU (CAM-ICU) measurement tool. The CAM-ICU is a binary (yes/no) scale for assessing the presence of delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Secondary Infection</measure>
    <time_frame>Up to day +14 following study enrollment.</time_frame>
    <description>Number of participants who develop secondary infections during and after steroid therapy. A secondary infection is defined as a new infection that develops after initiation of corticosteroid therapy, until 5 days after steroids are discontinued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Admission</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Number of subjects admitted to the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen-free Days</measure>
    <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
    <description>Number of days subjects did not require oxygen assistance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care as determined by the patient's primary team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker-adjusted Steroid Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
    <arm_group_label>Biomarker-adjusted Steroid Dosing</arm_group_label>
    <other_name>Biomarker guided steroid dosing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual care as determined by the patients treatment team.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For the Pneumonia arm of the study:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to hospital with community acquired pneumonia.&#xD;
&#xD;
          -  Acute respiratory failure SpO2/FiO2 &lt; 315 (SpO2&lt;90% on room air or &lt;97% on 2L NC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications or unwilling to use steroids by patient or provider&#xD;
&#xD;
          -  Refractory septic shock defined as a requirement of norepinephrine dose or equivalent&#xD;
             above &gt;0.1 microgram/kilogram/minute or 2 or more vasopressors&#xD;
&#xD;
          -  Pre-admission chronic use of steroids or other immunosuppressive medications&#xD;
&#xD;
          -  Adrenal insufficiency&#xD;
&#xD;
          -  Comfort care&#xD;
&#xD;
          -  Leukopenia &lt;1000/mm or neutropenia &lt;500/mm (except if attributable to pneumonia) and&#xD;
             HIV positive with a CD4 count &lt;100&#xD;
&#xD;
          -  Recent or past history of bone marrow or solid organ transplantation&#xD;
&#xD;
          -  Hospital admission in the previous 30 days&#xD;
&#xD;
          -  Suspected flare of Interstitial lung disease (infectious and non-infectious)&#xD;
&#xD;
          -  Positive influenza testing or high suspicion for influenza&#xD;
&#xD;
        For the COVID-19 arm of the study:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to hospital with COVID-19 pneumonia (high suspicion or confirmed by&#xD;
             positive SARS CoV-2 testing).&#xD;
&#xD;
          -  Acute respiratory failure SpO2/FiO2 &lt; 315 (SpO2&lt;90% on room air or &lt;97% on 2L NC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications or unwilling to use steroids by patient or provider&#xD;
&#xD;
          -  Refractory septic shock defined as a requirement of norepinephrine dose or equivalent&#xD;
             above &gt;0.1 microgram/kilogram/minute or 2 or more vasopressors&#xD;
&#xD;
          -  Pre-admission chronic use of steroids or other immunosuppressive medications&#xD;
&#xD;
          -  Adrenal insufficiency&#xD;
&#xD;
          -  Comfort care&#xD;
&#xD;
          -  Leukopenia &lt;1000/mm or neutropenia &lt;500/mm (except if attributable to pneumonia) and&#xD;
             HIV positive with a CD4 count &lt;100&#xD;
&#xD;
          -  Recent or past history of bone marrow or solid organ transplantation&#xD;
&#xD;
          -  Suspected flare of Interstitial lung disease (infectious and non-infectious)&#xD;
&#xD;
          -  Positive influenza testing or high suspicion for influenza&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hemang Yadav</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <results_first_submitted>September 2, 2021</results_first_submitted>
  <results_first_submitted_qc>September 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hemang Yadav</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pneumonia, steroid, COVID-19, SARS CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in any manuscript resulting from this research, after deidentification (text, tables, figures, and appendices) and the study protocol will be shared beginning 9 months and ending 36 months following article publication, to anyone who wishes to access the data. Proposals should be directed to yadav.hemang@mayo.edu. To gain access, data requestors will need to sign a data access agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From 9 months to 36 months after article publication.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03852537/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Usual Care</title>
          <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Biomarker-adjusted Steroid Dosing</title>
          <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Usual Care</title>
          <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Biomarker-adjusted Steroid Dosing</title>
          <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="50.0" upper_limit="67.0"/>
                    <measurement group_id="B2" value="59.0" lower_limit="52.0" upper_limit="79.0"/>
                    <measurement group_id="B3" value="60.0" lower_limit="51.5" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing</title>
        <description>Number of eligible subjects to adhered to the timely initiation and daily corticosteroid treatment according to ESICM/Society of Critical Care Medicine SCCM clinical practice guideline (control group) or biomarker concordance (intervention group)</description>
        <time_frame>Within 30 days of enrollment in study.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing</title>
          <description>Number of eligible subjects to adhered to the timely initiation and daily corticosteroid treatment according to ESICM/Society of Critical Care Medicine SCCM clinical practice guideline (control group) or biomarker concordance (intervention group)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Number of subject deaths</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Number of subject deaths</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for High Flow Nasal Cannula Oxygen</title>
        <description>Number of subjects to need high flow nasal cannula oxygen</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for High Flow Nasal Cannula Oxygen</title>
          <description>Number of subjects to need high flow nasal cannula oxygen</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.494</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Noninvasive Mechanical Ventilation</title>
        <description>Assessed by the number of participants that required noninvasive mechanical ventilation.</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Noninvasive Mechanical Ventilation</title>
          <description>Assessed by the number of participants that required noninvasive mechanical ventilation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.666</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Invasive Mechanical Ventilation</title>
        <description>Assessed by the number of participants that required invasive mechanical ventilation.</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Invasive Mechanical Ventilation</title>
          <description>Assessed by the number of participants that required invasive mechanical ventilation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Organ Failure</title>
        <description>Organ failures measured by Sequential Organ Failure Assessment (SOFA). The overall score is based on 6 sub-scores respiratory system, neurologic system, cardiovascular system, hepatic system, coagulation, and renal system using an overall scale of 0-24, which 0=no organ failure, 24=complete organ failure.</description>
        <time_frame>Measured daily for approximately 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Organ Failure</title>
          <description>Organ failures measured by Sequential Organ Failure Assessment (SOFA). The overall score is based on 6 sub-scores respiratory system, neurologic system, cardiovascular system, hepatic system, coagulation, and renal system using an overall scale of 0-24, which 0=no organ failure, 24=complete organ failure.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="4.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onset Cardiac Arrhythmias</title>
        <description>Number of participants who develop arrhythmias identified by electrocardiogram or echocardiogram.</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onset Cardiac Arrhythmias</title>
          <description>Number of participants who develop arrhythmias identified by electrocardiogram or echocardiogram.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.477</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Injury</title>
        <description>Number of participants with evidence of myocardial injury determined by daily troponin peak and /or new diagnosis of Left Ventricular (LV) dysfunction (LVEF &lt;40%) or new diagnosis of cor pulmonale</description>
        <time_frame>Up to day +14 following study enrollment.</time_frame>
        <population>Data were missing for 8 subjects in the usual care arm and 4 subjects in the biomarker-adjusted steroid dosing arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Injury</title>
          <description>Number of participants with evidence of myocardial injury determined by daily troponin peak and /or new diagnosis of Left Ventricular (LV) dysfunction (LVEF &lt;40%) or new diagnosis of cor pulmonale</description>
          <population>Data were missing for 8 subjects in the usual care arm and 4 subjects in the biomarker-adjusted steroid dosing arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Dysfunction</title>
        <description>Number of subjects with new and/or worsening right ventricle (RV)/left ventricle (LV) dysfunction</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Dysfunction</title>
          <description>Number of subjects with new and/or worsening right ventricle (RV)/left ventricle (LV) dysfunction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Hyperglycemia</title>
        <description>Number of participants who have hyperglycemia while receiving corticosteroids. Hyperglycemia is defined as a consistently elevated blood sugar level requiring insulin administration.</description>
        <time_frame>Up to day +5 following study enrollment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Hyperglycemia</title>
          <description>Number of participants who have hyperglycemia while receiving corticosteroids. Hyperglycemia is defined as a consistently elevated blood sugar level requiring insulin administration.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Delirium</title>
        <description>Number of participants who develop delirium while receiving corticosteroids. Delirium will be assessed by Confusion Assessment Method for the ICU (CAM-ICU) measurement tool. The CAM-ICU is a binary (yes/no) scale for assessing the presence of delirium.</description>
        <time_frame>Up to day +5 following study enrollment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Delirium</title>
          <description>Number of participants who develop delirium while receiving corticosteroids. Delirium will be assessed by Confusion Assessment Method for the ICU (CAM-ICU) measurement tool. The CAM-ICU is a binary (yes/no) scale for assessing the presence of delirium.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Secondary Infection</title>
        <description>Number of participants who develop secondary infections during and after steroid therapy. A secondary infection is defined as a new infection that develops after initiation of corticosteroid therapy, until 5 days after steroids are discontinued.</description>
        <time_frame>Up to day +14 following study enrollment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Secondary Infection</title>
          <description>Number of participants who develop secondary infections during and after steroid therapy. A secondary infection is defined as a new infection that develops after initiation of corticosteroid therapy, until 5 days after steroids are discontinued.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Admission</title>
        <description>Number of subjects admitted to the ICU</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Admission</title>
          <description>Number of subjects admitted to the ICU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.213</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen-free Days</title>
        <description>Number of days subjects did not require oxygen assistance.</description>
        <time_frame>Within hospitalization or 30 days of study enrollment (whichever is sooner)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker-adjusted Steroid Dosing</title>
            <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen-free Days</title>
          <description>Number of days subjects did not require oxygen assistance.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="17.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="24.0" lower_limit="22.0" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline to end of study for a total of approximately 90 days on all participants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care</title>
          <description>Corticosteroid use and dosing determined by the patient's primary team for standard of care.&#xD;
Usual Care: Corticosteroid use and dosing determined by the patients treatment team for standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Biomarker-adjusted Steroid Dosing</title>
          <description>Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP &lt; 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level &gt; 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).&#xD;
Methylprednisolone: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hemang Yadav, MBBS, MS</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-3958</phone>
      <email>Yadav.Hemang@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

